Thus, our present study, supported with strong methodology, provide novel therapeutic pathway, involving G6PD, Cyclin E1 and MMP9, that can be considered in future for ccRCC treatment. The gene discussed is MMP9; the disease is nonpapillary renal cell carcinoma.